Literature DB >> 12703669

Use of very low-dose naltrexone during opiate detoxification.

Paolo Mannelli1, Edward Gottheil, Antonio Buonanno, Sergio De Risio.   

Abstract

The use of antagonist drugs to reduce the duration of opiate detoxification severely enhances withdrawal symptoms. To investigate the feasibility of administering antagonists with opiates without intense withdrawal during detoxification, 5 methadone maintained patients were evaluated while tapering methadone and receiving at the same time very low (0.125 mg), then increasing daily doses of naltrexone in the course of a 6-day, day hospital treatment. Reduced quantities of adjunctive medications were administered, as compared to the standard protocols, the treatment was completed without incidents or particular discomfort and all patients were easily induced to naltrexone maintenance by the day of discharge. Controlled studies will clarify whether very low-dose naltrexone provides a safe and comfortable detoxification technique to reduce withdrawal intensity and duration without the problems of heavy sedation, as suggested by the description of these clinical cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12703669     DOI: 10.1300/J069v22n02_05

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  9 in total

1.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

2.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Authors:  Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2017-01-10       Impact factor: 18.112

3.  Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

4.  Early outcomes following low dose naltrexone enhancement of opioid detoxification.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathleen Peindl; Edward Gottheil; Li-Tzy Wu; David A Gorelick
Journal:  Am J Addict       Date:  2009 Mar-Apr

Review 5.  Potential uses of naltrexone in emergency department patients with opioid use disorder.

Authors:  Evan Stuart Bradley; David Liss; Stephanie Pepper Carreiro; David Eric Brush; Kavita Babu
Journal:  Clin Toxicol (Phila)       Date:  2019-03-04       Impact factor: 4.467

6.  Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety.

Authors:  Reza Afshari; Majid Khadem-Rezaiyan; Hoda Khatibi Moghadam; Mahdi Talebi
Journal:  Toxicol Res       Date:  2019-11-21

7.  Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathi Peindl; David A Gorelick; Li-Tzy Wu; Edward Gottheil
Journal:  Addict Biol       Date:  2008-08-19       Impact factor: 4.280

8.  Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.

Authors:  Paolo Mannelli; Kathleen S Peindl; Li-Tzy Wu
Journal:  Subst Abuse Rehabil       Date:  2011-06

Review 9.  Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.

Authors:  Adam Bisaga; Paolo Mannelli; Maria A Sullivan; Suzanne K Vosburg; Peggy Compton; George E Woody; Thomas R Kosten
Journal:  Am J Addict       Date:  2018-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.